NCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
Clinical Trials
7 trialsNCT06031688 2026-01-23
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Recruiting
NCT06908993 2025-12-17
COMET
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT05782361 2025-08-20
POTENT
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT05159245 2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05439993 2022-07-05
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
Phase 1/2 Recruiting